Operating Income (Loss) of BriaCell Therapeutics Corp. from 31 Jul 2021 to 31 Jan 2026

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
BriaCell Therapeutics Corp. quarterly and annual Operating Income (Loss) in USD history and change rate from 31 Jul 2021 to 31 Jan 2026.
  • BriaCell Therapeutics Corp. Operating Income (Loss) for the quarter ending 31 Jan 2026 was $7,531,266, a 5% decline year-over-year.
  • BriaCell Therapeutics Corp. Operating Income (Loss) for the twelve months ending 31 Jan 2026 was $30,736,737, a 13% decline year-over-year.
  • BriaCell Therapeutics Corp. annual Operating Income (Loss) for 2025 was $27,204,803, a 18% increase from 2024.
  • BriaCell Therapeutics Corp. annual Operating Income (Loss) for 2024 was $33,330,076, a 43% decline from 2023.
  • BriaCell Therapeutics Corp. annual Operating Income (Loss) for 2023 was $23,272,264, a 52% decline from 2022.
Source SEC data
View on sec.gov
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Change (%)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Change (%)

BriaCell Therapeutics Corp. Quarterly Operating Income (Loss) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $30,736,737 $7,531,266 -$361,823 -5% 01 Nov 2025 31 Jan 2026 10-Q 10 Mar 2026 2026 Q2
Q3 2025 $30,374,914 $8,322,943 -$3,170,111 -62% 01 Aug 2025 31 Oct 2025 10-Q 11 Dec 2025 2026 Q1
Q2 2025 $27,204,803 $8,554,273 -$2,786,319 -48% 01 May 2025 31 Jul 2025 10-K 16 Oct 2025 2025 FY
Q1 2025 $24,418,484 $6,328,255 +$2,901,393 +31% 01 Feb 2025 30 Apr 2025 10-Q 16 Jun 2025 2025 Q3
Q4 2024 $27,319,877 $7,169,443 +$2,660,003 +27% 01 Nov 2024 31 Jan 2025 10-Q 10 Mar 2026 2026 Q2
Q3 2024 $29,979,880 $5,152,832 +$3,350,196 +39% 01 Aug 2024 31 Oct 2024 10-Q 11 Dec 2025 2026 Q1
Q2 2024 $33,330,076 $5,767,954 +$1,937,807 +25% 01 May 2024 31 Jul 2024 10-K 16 Oct 2025 2025 FY
Q1 2024 $35,267,883 $9,229,648 -$3,552,619 -63% 01 Feb 2024 30 Apr 2024 10-Q 16 Jun 2025 2025 Q3
Q4 2023 $31,715,264 $9,829,446 -$5,343,123 -119% 01 Nov 2023 31 Jan 2024 10-Q 12 Mar 2025 2025 Q2
Q3 2023 $26,372,141 $8,503,028 -$3,099,877 -57% 01 Aug 2023 31 Oct 2023 10-Q 16 Dec 2024 2025 Q1
Q2 2023 $23,272,264 $7,705,761 -$2,471,698 -47% 01 May 2023 31 Jul 2023 10-K 29 Oct 2024 2024 FY
Q1 2023 $20,800,566 $5,677,029 -$1,553,769 -38% 01 Feb 2023 30 Apr 2023 10-Q 14 Jun 2024 2024 Q3
Q4 2022 $19,246,797 $4,486,323 -$839,514 -23% 01 Nov 2022 31 Jan 2023 10-Q 18 Mar 2024 2024 Q2
Q3 2022 $18,407,283 $5,403,151 -$3,118,342 -136% 01 Aug 2022 31 Oct 2022 10-Q 14 Dec 2023 2024 Q1
Q2 2022 $15,288,941 $5,234,063 01 May 2022 31 Jul 2022 10-K 25 Oct 2023 2023 FY
Q1 2022 $4,123,260 01 Feb 2022 30 Apr 2022 10-Q 14 Jun 2023 2023 Q3
Q4 2021 $3,646,809 01 Nov 2021 31 Jan 2022 10-Q 16 Mar 2023 2023 Q2
Q3 2021 $2,284,809 01 Aug 2021 31 Oct 2021 10-Q 14 Dec 2022 2023 Q1

BriaCell Therapeutics Corp. Annual Operating Income (Loss) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $27,204,803 +$6,125,273 +18% 01 Aug 2024 31 Jul 2025 10-K 16 Oct 2025 2025 FY
2024 $33,330,076 -$10,057,812 -43% 01 Aug 2023 31 Jul 2024 10-K 16 Oct 2025 2025 FY
2023 $23,272,264 -$7,983,323 -52% 01 Aug 2022 31 Jul 2023 10-K 29 Oct 2024 2024 FY
2022 $15,288,941 -$8,312,906 -119% 01 Aug 2021 31 Jul 2022 10-K 25 Oct 2023 2023 FY
2021 $6,976,035 01 Aug 2020 31 Jul 2021 10-K 28 Oct 2022 2022 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.